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pared from four resource categories: chemotherapy acquisition,
drug administration, hospitalisation associated with adverse
events, and other medical resources. Italian health care unit costs
were obtained from published sources. RESULTS: Lowest treat-
ment costs were incurred by the Gem/Cis group (8092€), fol-
lowed by the Vin/Cis and Pac/Carbo groups (9320€ and 11,203€
respectively). The cost difference between the Gem/Cis and
Pac/Carbo regimens was due to the difference in chemotherapy
acquisition costs (3732€), which offset the increased costs for
drug administration (499€) and other medical resources (524€)
in the Gem/Cis group. The overall per-patient cost saving for
Gem/Cis versus Vin/Cis (1227€) was primarily due to reduced
hospitalisations for adverse events (2223€) despite the increased
acquisition costs for Gem/Cis (1422€). CONCLUSIONS: Based
on data collected during a randomised clinical trial, ﬁrst-line use
of Gem/Cis offers potential cost savings compared to other plat-
inum-based third-generation agent combinations in the treat-
ment of advanced NSCLC in Italy. Since these savings relate
primarily to chemotherapy acquisition and hospitalisation costs
due to adverse events, they are likely to be transferred to the
community setting.
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OBJECTIVE: As the prognosis of non-small cell lung cancer
(NSCLC) patients after ﬁrst and second line treatment remains
poor, new targeted strategies in third-line treatment are of high
interest. This study estimates the cost-effectiveness of geﬁtinib
compared to Best Supportive Care (BSC) in the Dutch health care
setting. METHODS: A Markov model was designed to evaluate
the lifetime clinical and economic outcomes of geﬁtinib treat-
ment and BSC. The model was calibrated using clinical data from
randomized clinical studies, a Delphi panel (n = 10), patient chart
analysis and literature for costs data. The analysis was performed
from a societal perspective for a hypothetical cohort of advanced
NSCLC patients, who have failed two chemotherapy regimens.
Only direct costs related to the treatment of severe adverse
events, radiotherapy, evaluation of disease progression and ter-
minal care were considered. The time horizon related to mor-
tality, estimated the costs from start of therapy until death. Both
costs and effects were discounted at 4% pa. RESULTS: With an
assumed difference in survival of 2.45 months between geﬁtinib
and BSC, the model predicts survival of 0.573 life years (LY) for
BSC and 0.790 LY for geﬁtinib. Total costs related to BSC and
geﬁtinib treatment until death are 8444€ and 15,272€ respec-
tively. The average cost-effectiveness ratio of geﬁtinib is higher
than BSC (19,326€/LY versus 14,745€/LY). The incremental
cost-effectiveness ratio of geﬁtinib compared to BSC is 31,380€
per LYG. Applying the threshold proposed by the Institute for
Medical Technology Assessment for disease with highest burden
(45,000€/QALY), geﬁtinib is cost-effective in 73% of advanced
NSCLC patients compared to BSC in third-line therapy. CON-
CLUSION: In addition to its convenient oral administration, its
favorable tolerability proﬁle, geﬁtinib is cost-effective compared
to not only BSC but also compared to heart or liver transplan-
tations. “Iressa” is a trademark of the AstraZeneca group of
companies.
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OBJECTIVES: To evaluate the costs in Spain of treating
advanced non-small-cell lung cancer (NSCLC) with gemcitabine
plus cisplatin (Gem/Cis) in comparison with other platinum-
based combination chemotherapy regimens, and to compare the
ﬁndings with previously published cost analyses. METHODS: A
retrospective economic analysis was conducted based on medical
resource utilisation in a randomised controlled trial (Scagliotti 
et al. 2002), which found that Gem/Cis demonstrated compara-
ble efﬁcacy to paclitaxel/carboplatin (Pac/Carbo) and vinorel-
bine/cisplatin (Vin/Cis) regimens in 612 patients with advanced
NSCLC. Treatment costs were compared across four main
resource categories: chemotherapy acquisition, drug administra-
tion, hospitalisation episodes, and other medical resources.
Spanish Health Care unit costs were drawn from published lit-
erature and public sources. Results were compared with those
published by Schiller et al. (2004). RESULTS: The mean total
treatment-related costs of Gem/Cis were 5578€ per patient,
which was lower than those seen with Pac/Carbo (11,541€) or
Vin/Cis (6084€). Chemotherapy acquisition was the major cost
driver for Gem/Cis (63% of total costs) and Pac/Carbo (90% of
total costs), but other component costs, especially hospitalisa-
tions, were considerable for the Vin/Cis regimen (36% of total
costs). The total costs per patient are comparable to those
reported for Spain by Schiller et al. (2004) with calculations
based on Comella et al. (2000) (Gem/Cis 4072€; Vin/Cis 4899€)
and Schiller et al. (2002) (Gem/Cis 5082€; Pac/Carbo 840€),
trials employing different dosing schedules. CONCLUSIONS:
Cost-minimisation analyses based on chemotherapy and
resource utilisation in randomised controlled clinical trials
demonstrate that Gem/Cis has lower total treatment costs from
the perspective of the Spanish national health system than
Pac/Carbo and Vin/Cis for the treatment of advanced NSCLC.
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CELL LUNG CANCER (NSCLC) IN THE UK
Ratcliffe AE1, Beard SM2,Wolowacz S2
1AstraZeneca, Luton, Bedfordshire, UK; 2RTI Health Solutions,
Manchester, UK
OBJECTIVE: To assess the cost-effectiveness of geﬁtinib
(“Iressa”) compared to BSC in patients with refractory advanced
NSCLC in the UK National Health Service (NHS). METHODS:
A probabilistic model was developed to assess the cost-
effectiveness (and associated uncertainty) of geﬁtinib compared
with BSC in patients with refractory advanced NSCLC in the UK
NHS. Efﬁcacy data were drawn from two independent sources:
data for geﬁtinib were derived from IDEAL II (patients refrac-
tory to platinum and docetaxel) and data for BSC were derived
from a literature review (BSC arm of a randomised controlled
trial in second-line advanced NSCLC). Cost data were collected
from the perspective of the UK NHS. In the absence of a UK
price for geﬁtinib, the pre-approval sales price in France (1950€)
was converted into UK prices (approximately £1300). Resource
utilisation and cost data for geﬁtinib were derived from pub-
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lished data and expert clinical opinion. Conservative assump-
tions were made for geﬁtinib in the base-case analysis; namely
that geﬁtinib patients consumed the same supportive care
resources as patients treated with a combination of mitomycin,
ifosfamide and cisplatin, which is approximately 20% higher
than for BSC. RESULTS: Additional costs of geﬁtinib compared
with BSC were estimated to be approximately £5000. The addi-
tional life expectancy was estimated to be approximately 3
months giving an incremental cost per life year gained (LYG)
ratio of approximately £22k (based on mean of probabilistic
simulations). The ratio falls to approximately £17k per LYG
when equivalent palliative care costs are assumed. CONCLU-
SIONS: According to this model, the results show that geﬁtinib
is likely to be a cost-effective strategy in the UK for the treat-
ment of advanced NSCLC patients refractory to platinum and
docetaxel compared with best supportive care. The model’s con-
servative assumptions would further support this conclusion.
“Iressa” is a trademark of the AstraZeneca group of companies.
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OBJECTIVES: To systematically evaluate the impact of the
screening interval (SI) on effectiveness and cost-effectiveness of
different cervical cancer screening strategies (CCS) in Germany
using a decision analytic approach.METHODS: A decision-
analytic Markov model, was used to evaluate the longterm clin-
ical and economic outcomes of different SI (1, 2, 3, 5 years) for
the following CCS: 1) no screening; 2) conventional Papanico-
laou test (Pap); 3) liquid-based preparation (LP); 4) automated
smear analysis (AA); and 5) a combination of liquid-based
preparation and automated smear analysis. German clinical, epi-
demiological and economic data were used. Outcomes were
detected/prevented cervical cancer (CC) cases and deaths, life
expectancy, lifetime costs, and discounted incremental cost-
effectiveness ratios (ICER). A societal perspective and 3% annual
discount rate were considered. RESULTS: Medical effectiveness
increased with increasing screening frequency in all CCS. Incre-
mental effectiveness of new CCS versus Pap decreased with
increasing screening frequency and test sensitivity. Screening
every 5 years resulted in 252–699, annual screening in 3–38
detected CC cases/100,000 women. The ICER for annual Pap
versus no screening was 6600€/LYS, and for screening every 2,
3, or 5 years 2300€/LYS, 1400€/LYS, 140€/LYS, respectively.
Compared to Pap, annual screening with new CCS resulted 
in ICERs of 220,000€/LYS (AA)—1,083,000€/LYS (LP+AA).
Longer screening intervals resulted in lower ICERs. Results were
sensitive when varying values of screening test sensitivities or
screening adherence of women. CONCLUSIONS: Annual Pap
screening, the current clinical standard in Germany, is both effec-
tive and cost-effective. However, screening with new screening
techniques every 2 years may be equally effective as annual Pap,
but less costly. A reduction in screening frequency should be crit-
ically discussed within the context of improving screening adher-
ence of women.
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OBJECTIVES: Five polychemotherapy regimens: gemcitabine-
cisplatine (Gem/Cis), vinorelbine-cisplatine (Vin/Cis), docetaxel-
cisplatine (Doc/Cis), paclitaxel-cisplatine (Pac/Cis) and
paclitaxel-carboplatine (Pac/Car), are commonly used in ﬁrst-
line treatment of advanced non-small cell lung cancer. Whereas
taxanes have to be administered within a conventional day-
hospitalization setting, gemcitabine and vinorelbine could be
administrated without platinium in home-hospitalization. The
purpose of the study is to ﬁnd out which case management min-
imizes costs for the French National Health Insurance while
ensuring patient safety. METHODS: A Markov model was con-
structed in order to estimate the cost consequences of home
administrations for gemcitabine and vinorelbine chemotherapies
(without cisplatine) compared to taxanes administrated only at
hospitals. Transitional probabilities are based on Schiller (2002)
and Scagliotti (2002) published controlled trials. In all cases, no
differences in efﬁcacy were found between all regimens. A cost
minimization analysis was performed. The costs were calculated
by adding DRG costs, onerous drug costs reimbursed over DRGs
and transportation expenses. Platinium components included in
DRG costs were not added. Costs of febrile neutropenia, blood
transfusions, nausea and vomiting, diagnosis and palliative care,
were taken into account. A univariate sensitivity analysis was
performed, in order to identify the main cost drivers. RESULTS:
With the conservative assumption of no differences in therapeu-
tic efﬁcacy and no more than two home administrations per
cycle, Gem/Cis and Vin/Cis appear with annual follow-up costs
of 16,815€ and 17,200€ respectively. Taxanes (Doc/Cis, Pac/Cis
and Pac/Car) hospital administration have annual follow-up
costs of 20,800€, 22,720€, and 25,760€ respectively. CON-
CLUSION: When the patient’s safety and his will to receive
chemotherapy at home are met in an environment where equiv-
alent efﬁcacy exists between chemotherapy regimens, an eco-
nomic analysis can quantify the ﬁnancial consequences on the
French Health Insurance, of the drug choice made by prescribers.
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OBJECTIVES: Gemcitabine/cisplatin (GC) is one of several
novel chemotherapy regimens available for the treatment of non-
small cell lung cancer. An economic cost-minimisation analysis
using a phase III randomized clinical trial was performed to 
evaluate the relative total cost of treatment of GC with other
novel agent regimens in Taiwan. METHODS: The analysis was
based upon the trial published by Schiller et al. (2002) with GC,
paclitaxel/cisplatin (PC), paclitaxel/carboplatin (PCA) and doc-
etaxel/cisplatin (DC) as treatment arms. The economic evalua-
tions were conducted using the retrospective model in European
countries published by Schiller et al. (2004). Taiwan costs were
drawn from Taiwan National Health Insurance Reimbursement
